Shamburg News · 8-K filed Nov 9, 2026, 7:49 AM EST

CorMedix to Acquire Substantially All Assets of Heron Therapeutics for $145 Million Cash Plus Stock

CRMD · CorMedix Inc.

  • Material agreement
  • Acquisition
  • Financing
  • Reg FD disclosure
  • Materiality: high

On November 8, 2026, CorMedix entered into an Asset Purchase Agreement to acquire substantially all assets of Heron Therapeutics for $145.0 million in cash subject to adjustments, 14,583,333 shares of CorMedix common stock, a 5.0% royalty on certain net sales above $25.0 million in 2027 through 2029, and earn-out payments of up to $55.0 million tied to 2028 ZYNRELEF net sales. The company also entered a senior secured term loan agreement with Pharmakon-managed funds providing up to $150.0 million, with a $75.0 million Tranche A to fund the transaction. Closing is subject to Heron stockholder approval, HSR clearance, and other customary conditions, and Heron agreed to pay a $4.0 million termination fee in specified circumstances.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 2.03, 3.02, 7.01, 9.01, accession 0001213900-26-117213.

Written from the filing by Shamburg Markets. Figures are as reported by the company.